Nuvo Pharmaceuticals Inc
TSX:MRV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Nuvo Pharmaceuticals Inc
TSX:MRV
|
CA |
|
V
|
Valneva SE
XMUN:AYJ
|
FR |
|
Cooper-Standard Holdings Inc
NYSE:CPS
|
US |
|
C
|
Cintas Corp
XETRA:CIT
|
US |
|
Ariston Holding NV
MIL:ARIS
|
IT |
|
S
|
SF Urban Properties AG
F:1Z9
|
CH |
|
Godfrey Phillips India Ltd
NSE:GODFRYPHLP
|
IN |
|
I
|
Intesa Sanpaolo SpA
XHAM:IES
|
IT |
|
I
|
IAMGOLD Corp
DUS:IAL
|
CA |
|
PowerSchool Holdings Inc
NYSE:PWSC
|
US |
|
M
|
Mitsubishi Heavy Industries Ltd
XMUN:MIH
|
JP |
|
Harmony Gold Mining Company Ltd
F:HAM1
|
ZA |
|
BioNTech SE
NASDAQ:BNTX
|
DE |
|
C
|
China Telecom Corp Ltd
XMUN:ZCH
|
CN |
|
I
|
Itochu Corp
XMUN:IOC
|
JP |
|
W
|
Wharf Holdings Ltd
F:WHA
|
HK |
|
M
|
MGIC Investment Corp
XMUN:MGC
|
US |
|
S
|
Silvercorp Metals Inc
XMUN:S9Y
|
CA |
|
Ferrovial SA
F:UFG
|
ES |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is MRV's stock price target?
Not Available
MRV does not have any price targets made by Wall Street professionals.
What is the Revenue forecast for Nuvo Pharmaceuticals Inc?
Projected CAGR
79%
Over the last 13 years, the compound annual growth rate for Revenue has been 15%. The projected CAGR for the next 12 years is 79%.
What is the Operating Income forecast for Nuvo Pharmaceuticals Inc?
Projected CAGR
170%
The compound annual growth rate for Operating Income over the next 7 years is 170%.